Ligand Pharm (LGND)

May 14, 2025, 7:00 AM EDT - 22 days ago

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

May 8, 2025, 2:19 PM EDT - 4 weeks ago

Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 4 weeks ago

Ligand Reports First Quarter 2025 Financial Results

May 1, 2025, 7:00 AM EDT - 5 weeks ago

Ligand to Participate in May Investor Conferences

Apr 24, 2025, 7:00 AM EDT - 6 weeks ago

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 17, 2025, 6:00 AM EDT - 7 weeks ago

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

Mar 3, 2025, 7:00 AM EST - 3 months ago

Ligand to Participate in March Investor Conferences

Feb 27, 2025, 3:06 PM EST - 3 months ago

Ligand Pharmaceuticals Incorporated (LGND) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:00 AM EST - 3 months ago

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 25, 2025, 7:00 AM EST - 3 months ago

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

XOMA

Feb 13, 2025, 7:00 AM EST - 4 months ago

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Feb 6, 2025, 7:00 AM EST - 4 months ago

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 2:59 PM EST - 4 months ago

Looking Back On Ligand Pharmaceuticals

Jan 13, 2025, 6:10 PM EST - 5 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Dec 10, 2024, 9:00 AM EST - 6 months ago

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

Nov 24, 2024, 6:50 AM EST - 6 months ago

Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies

Nov 14, 2024, 8:00 AM EST - 7 months ago

Ligand to Present at Stifel 2024 Healthcare Conference

Nov 8, 2024, 8:07 AM EST - 7 months ago

Ligand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 7 months ago

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Nov 1, 2024, 8:01 AM EDT - 7 months ago

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

Oct 23, 2024, 4:01 PM EDT - 8 months ago

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

Sep 6, 2024, 9:20 AM EDT - 9 months ago

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

TVTX

Aug 30, 2024, 4:04 AM EDT - 10 months ago

CD40 Ligand Market - Global Monoclonal Antibody, Polyclonal Antibody, Autoimmune Disease Treatment, Immunotherapy, Vaccine Development Forecast 2024-2030

Aug 20, 2024, 9:00 AM EDT - 10 months ago

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 6, 2024, 10:58 PM EDT - 10 months ago

Ligand Pharmaceuticals Incorporated (LGND) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:01 PM EDT - 10 months ago

Ligand Reports Second Quarter 2024 Financial Results

Jul 29, 2024, 2:43 PM EDT - 11 months ago

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Jul 24, 2024, 6:30 AM EDT - 11 months ago

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement

Jul 23, 2024, 4:01 PM EDT - 11 months ago

Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024

Jul 8, 2024, 7:00 AM EDT - 11 months ago

Ligand to Acquire APEIRON Biologics AG for $100 Million

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years

Jun 18, 2024, 8:00 AM EDT - 1 year ago

Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults

May 23, 2024, 4:59 PM EDT - 1 year ago

Ligand to Participate in Upcoming Investor Conferences

May 7, 2024, 11:03 PM EDT - 1 year ago

Ligand Pharmaceuticals Incorporated (LGND) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:00 PM EDT - 1 year ago

Ligand Reports First Quarter 2024 Financial Results

May 7, 2024, 7:30 AM EDT - 1 year ago

Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement

AGEN

Apr 29, 2024, 10:01 PM EDT - 1 year ago

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

Apr 23, 2024, 8:31 AM EDT - 1 year ago

Ligand to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 8, 2024, 8:15 AM EDT - 1 year ago

Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

Apr 3, 2024, 9:00 AM EDT - 1 year ago

Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™

Mar 5, 2024, 4:01 PM EST - 1 year ago

Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference

Mar 4, 2024, 8:00 AM EST - 1 year ago

Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 27, 2024, 11:32 AM EST - 1 year ago

Ligand Pharmaceuticals Inc. (LGND) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 7:00 AM EST - 1 year ago

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 22, 2024, 4:01 PM EST - 1 year ago

Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Feb 16, 2024, 8:00 AM EST - 1 year ago

Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires

Feb 13, 2024, 4:01 PM EST - 1 year ago

Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Feb 12, 2024, 5:00 AM EST - 1 year ago

Iambic Therapeutics Announces New Research Published in Nature Machine Intelligence Demonstrating the Capabilities of Its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures

Jan 5, 2024, 5:21 PM EST - 1 year ago

Ligand Pharma's at-home skin treatment gets FDA approval

Jan 5, 2024, 4:30 PM EST - 1 year ago

U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum